192 related articles for article (PubMed ID: 8641012)
1. Mechanism of action of OPC-8490 in human ventricular myocardium.
Focaccio A; Peeters G; Movsesian M; Roden R; Eki Y; Krall J; Bristow MR
Circulation; 1996 Feb; 93(4):817-25. PubMed ID: 8641012
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent saterinone in guinea pig myocardium.
Brunkhorst D; von der Leyen H; Meyer W; Schmidt-Schumacher C; Scholz H
Arzneimittelforschung; 1988 Sep; 38(9):1293-8. PubMed ID: 2852013
[TBL] [Abstract][Full Text] [Related]
3. Positive inotropic and chronotropic effects of toborinone and its electrophysiological properties in the isolated hearts of rabbits and guinea-pigs.
Takase H; Orito K; Mori T; Fujiki H; Sekiguchi K; Tominaga M; Iijima T
Arzneimittelforschung; 1996 Jun; 46(6):579-86. PubMed ID: 8767347
[TBL] [Abstract][Full Text] [Related]
4. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.
von der Leyen H; Mende U; Meyer W; Neumann J; Nose M; Schmitz W; Scholz H; Starbatty J; Stein B; Wenzlaff H
Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):90-100. PubMed ID: 1723153
[TBL] [Abstract][Full Text] [Related]
5. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine.
Katano Y; Endoh M
J Cardiovasc Pharmacol; 1992; 20(5):715-22. PubMed ID: 1280732
[TBL] [Abstract][Full Text] [Related]
6. Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram.
Shahid M; Nicholson CD
Naunyn Schmiedebergs Arch Pharmacol; 1990 Dec; 342(6):698-705. PubMed ID: 1710786
[TBL] [Abstract][Full Text] [Related]
7. Subcellular mechanism of the positive inotropic effect of a new quinolinone derivative OPC-8490 on the dog ventricular myocardium.
Endoh M; Satoh H; Norota I; Hirano K; Hosokawa T
Heart Vessels; 1991; 6(3):158-67. PubMed ID: 1655692
[TBL] [Abstract][Full Text] [Related]
8. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism.
Ahn HS; Eardley D; Watkins R; Prioli N
Biochem Pharmacol; 1986 Apr; 35(7):1113-21. PubMed ID: 2421728
[TBL] [Abstract][Full Text] [Related]
9. Positive inotropic and negative chronotropic effects of OPC-8490, a newly developed cardiotonic, in isolated, blood-perfused canine heart preparations.
Furukawa Y; Akahane K; Haniuda M; Chiba S
Jpn Heart J; 1989 May; 30(3):387-98. PubMed ID: 2552190
[TBL] [Abstract][Full Text] [Related]
10. The phosphodiesterase 3 inhibitor cilostamide enhances inotropic responses to glucagon but not to dobutamine in rat ventricular myocardium.
Juan-Fita MJ; Vargas ML; Hernández J
Eur J Pharmacol; 2005 Apr; 512(2-3):207-13. PubMed ID: 15840406
[TBL] [Abstract][Full Text] [Related]
11. Positive inotropic activity of 5-amino-6-cyano-1,3-dimethyl-1,2,3,4-tetrahydropyrido[2,3-d]pyrim idine-2,4-dione in cardiac muscle from guinea-pig and man. Part 6: Compounds with positive inotropic activity.
Heber D; Heers C; Ravens U
Pharmazie; 1993 Jul; 48(7):537-41. PubMed ID: 7692456
[TBL] [Abstract][Full Text] [Related]
12. New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endogenous adenosine, and inhibition of cardiac type III phosphodiesterase.
Floreani M; Fossa P; Gessi S; Mosti L; Borea PA; Dorigo P
Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb; 367(2):109-18. PubMed ID: 12595951
[TBL] [Abstract][Full Text] [Related]
13. The inotropic mechanism of the phosphodiesterase inhibitor OPC 3911 alone and in combination with rolipram, studied in papillary muscles of ferret and guinea-pig and isolated myocytes of guinea-pig ventricular muscle.
Mörner SE; Arlock P; Lindgren S
Acta Physiol Scand; 1994 Mar; 150(3):325-34. PubMed ID: 8010139
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular actions of OPC-18790: a novel positive inotropic agent with little chronotropic action.
Hosokawa T; Mori T; Fujiki H; Kinoshita S; Takemoto K; Imaizumi T; Noda T; Ohura M; Tominaga M; Yabuuchi Y
Heart Vessels; 1992; 7(2):66-75. PubMed ID: 1328145
[TBL] [Abstract][Full Text] [Related]
15. Implication of cyclic AMP in the positive inotropic effects of cyclic GMP-inhibited cyclic AMP phosphodiesterase inhibitors on guinea pig isolated left atria.
Muller B; Lugnier C; Stoclet JC
J Cardiovasc Pharmacol; 1990 Mar; 15(3):444-51. PubMed ID: 1691369
[TBL] [Abstract][Full Text] [Related]
16. Mode and mechanism of action of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), a novel positive inotropic drug, on the dog heart.
Taira N; Endoh M; Iijima T; Satoh K; Yanagisawa T; Yamashita S; Maruyama M; Kawada M; Morita T; Wada Y
Arzneimittelforschung; 1984; 34(3A):347-55. PubMed ID: 6331465
[TBL] [Abstract][Full Text] [Related]
17. Relaxant effects of the selective phosphodiesterase inhibitors milrinone and OPC 3911 on isolated human mesenteric vessels.
Lindgren S; Andersson KE; Belfrage P; Degerman E; Manganiello VC
Pharmacol Toxicol; 1989 May; 64(5):440-5. PubMed ID: 2549528
[TBL] [Abstract][Full Text] [Related]
18. Effects of a novel cardiotonic agent (+-)-6-[3-(3,4-dimethoxybenzylamino)-2-hydroxypropoxy]-2(1H)-quinolino ne (OPC-18790) on contractile force, cyclic AMP level, and aequorin light transients in dog ventricular myocardium.
Endoh M; Kawabata Y; Katano Y; Norota I
J Cardiovasc Pharmacol; 1994 May; 23(5):723-30. PubMed ID: 7521454
[TBL] [Abstract][Full Text] [Related]
19. Electropharmacologic effects of a new phosphodiesterase III inhibitor, toborinone (OPC-18790), assessed in an in vivo canine model.
Sugiyama A; Satoh Y; Hashimoto K
J Cardiovasc Pharmacol; 2001 Aug; 38(2):268-77. PubMed ID: 11483877
[TBL] [Abstract][Full Text] [Related]
20. 4-(4-Guanidinobenzoyl)-2-imidazolones and related compounds: phosphodiesterase inhibitors and novel cardiotonics with combined histamine H2 receptor agonist and PDE III inhibitor activity.
Glass D; Buschauer A; Tenor H; Bartel S; Will-Shahab L; Krause EG
Arch Pharm (Weinheim); 1995 Oct; 328(10):709-19. PubMed ID: 8554460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
